ロード中...
EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
PURPOSE: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of advanced cancers with these mutations remains elusive, without an approved inhibitor. EXPERIMENTAL DESIGN: Preclinical mode...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295229/ https://ncbi.nlm.nih.gov/pubmed/30154228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1541 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|